Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Modeling SARS-CoV-2 in mice: Among the research tools necessary to develop medical interventions to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, high on the list are informative animal models with which to study viral pathogenesis. Gu et al. developed a mouse model in which a SARS-CoV-2 strain was infectious and could cause an inflammatory response and moderate pneumonia. Adaptation of this viral strain in the mouse appeared to be dependent on a critical amino acid change, Asn 501 to Tyr (N501Y), within the receptor-binding domain of the viral spike protein. The new mouse model was used to study neutralizing antibodies and a vaccine candidate against the virus. Science , this issue p. 1603
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although mouse models have the most information available about their biology and many research tools, the ACE2 receptor is significantly different between mice and humans; so mouse models most often use a humanized ACE2 or lung passage to overcome this obstacle. 177-179”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [179]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citationA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationDipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,911
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Self-citationTai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654
Self-citationImmunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Self-citationDevelopment of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Self-citationCarsana, L., Sonzogni, A., Nasr, A., Rossi, R. S., Pellegrinelli, A., Zerbi, P., Rech, R., Colombo, R., Antinori, S., Corbellino, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30434-5 · Cited by 1,396
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Self-citationAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,048
Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2787-6 · Cited by 798
Self-citationLiu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 694
Self-citationSARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P. J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 694
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C., Liu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04442-5 · Cited by 654
Self-citationVolz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
“Consistent with a recent report (Gu et al., 2020; Chen et al., 2021;Montagutelli et al., 2021), theBeta variant could infect wild-type BALB/c mice and replicate in their lungs (Figure 1Q), likely due to mutations in the spike such as K417N, E484K, and N501Y.”
Self-citationXie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2022) · Nature · doi:10.1038/s41586-021-04245-0 · Cited by 572
The origins of SARS-CoV-2: A critical review
Holmes, E. C., Goldstein, S. A., Rasmussen, A. L., Robertson, D. L., Crits-Christoph, A., Wertheim, J. O., Anthony, S. J., Barclay, W. S., Boni, M. F., Doherty, P. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.017 · Cited by 509
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
SARS-CoV-2 variants and ending the COVID-19 pandemic
Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S. S. A., & Sridhar, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00370-6 · Cited by 519
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. (2021) · Science · doi:10.1126/science.abg6105 · Cited by 515
“One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5).”
BackgroundNeutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Sarkar, R., Türeci, Ö., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.18.426984 · Cited by 515
COVID-19 vaccine development: milestones, lessons and prospects
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 434
Self-citationReduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
“Effect on ACE2 affinity It has been reported that mutations at 501 can increase affinity for ACE2 (Starr et al., 2020; Gu et al., 2020), although these data are not for the mutation to Y.”
BackgroundAfter the pandemic: perspectives on the future trajectory of COVID-19
Telenti, A., Arvin, A., Corey, L., Corti, D., Diamond, M. S., García-Sastre, A., Garry, R. F., Holmes, E. C., Pang, P. S., & Virgin, H. W. (2021) · Nature · doi:10.1038/s41586-021-03792-w · Cited by 426
The emergence, genomic diversity and global spread of SARS-CoV-2
Li, J., Lai, S., Gao, G. F., & Shi, W. (2021) · Nature · doi:10.1038/s41586-021-04188-6 · Cited by 413
Self-citationInfluenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz-Cherry, S. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00542-7 · Cited by 402
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 414
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
Gobeil, S. M.-C., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Stalls, V., Kopp, M. F., Manne, K., Li, D., Wiehe, K., et al. (2021) · Science · doi:10.1126/science.abi6226 · Cited by 394
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
To, K. K.-W., Sridhar, S., Chiu, K. H.-Y., Hung, D. L.-L., Li, X., Hung, I. F.-N., Tam, A. R., Chung, T. W.-H., Chan, J. F.-W., Zhang, A. J.-X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1898291 · Cited by 344
Self-citationSARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 354
Self-citationThe variant gambit: COVID-19’s next move
Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 299
K18-hACE2 mice develop respiratory disease resembling severe COVID-19
Yinda, C. K., Port, J. R., Bushmaker, T., Offei Owusu, I., Purushotham, J. N., Avanzato, V. A., Fischer, R. J., Schulz, J. E., Holbrook, M. G., Hebner, M. J., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009195 · Cited by 302
Boudewijns, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, V., Seldeslachts, L., Van Weyenbergh, J., De Keyzer, C., Bervoets, L., Sharma, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19684-y · Cited by 263
Self-citationEvidence for a mouse origin of the SARS-CoV-2 Omicron variant
Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., & Qian, W. (2021) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.12.003 · Cited by 288
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gómez, C. E., Perdiguero, B., & Esteban, M. (2021) · Vaccines · doi:10.3390/vaccines9030243 · Cited by 264
Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70
Kemp, S. A., Meng, B., Ferriera, I. A., Datir, R., Harvey, W. T., Papa, G., Lytras, S., Collier, D. A., Mohamed, A., Gallo, G., et al. (2020) · doi:10.1101/2020.12.14.422555 · Cited by 252
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y.-C., Lu, R.-M., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 237
Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters
Osterrieder, N., Bertzbach, L. D., Dietert, K., Abdelgawad, A., Vladimirova, D., Kunec, D., Hoffmann, D., Beer, M., Gruber, A. D., & Trimpert, J. (2020) · Viruses · doi:10.3390/v12070779 · Cited by 226
van der Wijst, M. G. P., Vazquez, S. E., Hartoularos, G. C., Bastard, P., Grant, T., Bueno, R., Lee, D. S., Greenland, J. R., Sun, Y., Perez, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh2624 · Cited by 233
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227
Self-citationChi, W.-Y., Li, Y.-D., Huang, H.-C., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 215
Self-citationSARS-COV-2 Variants: Differences and Potential of Immune Evasion
Hirabara, S. M., Serdan, T. D. A., Gorjao, R., Masi, L. N., Pithon-Curi, T. C., Covas, D. T., Curi, R., & Durigon, E. L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781429 · Cited by 226
Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
Rosenke, K., Meade-White, K., Letko, M., Clancy, C., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1858177 · Cited by 229
Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution
Amicone, M., Borges, V., Alves, M. J., Isidro, J., Zé-Zé, L., Duarte, S., Vieira, L., Guiomar, R., Gomes, J. P., & Gordo, I. (2022) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoac010 · Cited by 208
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Chen, R. E., Winkler, E. S., Case, J. B., Aziati, I. D., Bricker, T. L., Joshi, A., Darling, T. L., Ying, B., Errico, J. M., Shrihari, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03720-y · Cited by 220
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses
Starr, T. N., Zepeda, S. K., Walls, A. C., Greaney, A. J., Alkhovsky, S., Veesler, D., & Bloom, J. D. (2022) · Nature · doi:10.1038/s41586-022-04464-z · Cited by 207
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
Malik, J. A., Ahmed, S., Mir, A., Shinde, M., Bender, O., Alshammari, F., Ansari, M., & Anwar, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.12.014 · Cited by 201
Wong, L.-Y. R., & Perlman, S. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00656-2 · Cited by 192
Luan, B., Wang, H., & Huynh, T. (2021) · FEBS Letters · doi:10.1002/1873-3468.14076 · Cited by 200
Self-citationExperimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants
Laffeber, C., de Koning, K., Kanaar, R., & Lebbink, J. H. G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167058 · Cited by 199
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M. C., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 197
Self-citationImmune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
Lazarevic, I., Pravica, V., Miljanovic, D., & Cupic, M. (2021) · Viruses · doi:10.3390/v13071192 · Cited by 189
van Oosterhout, C., Hall, N., Ly, H., & Tyler, K. M. (2021) · Virulence · doi:10.1080/21505594.2021.1877066 · Cited by 195
Zhu, X., Mannar, D., Srivastava, S. S., Berezuk, A. M., Demers, J.-P., Saville, J. W., Leopold, K., Li, W., Dimitrov, D. S., Tuttle, K. S., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001237 · Cited by 178
COVID-19, Myocarditis and Pericarditis
Fairweather, D., Beetler, D. J., Di Florio, D. N., Musigk, N., Heidecker, B., & Cooper, L. T. (2023) · Circulation Research · doi:10.1161/circresaha.123.321878 · Cited by 194
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Wong, L.-Y. R., Zheng, J., Wilhelmsen, K., Li, K., Ortiz, M. E., Schnicker, N. J., Thurman, A., Pezzulo, A. A., Szachowicz, P. J., Li, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04630-3 · Cited by 178
Animal and translational models of SARS-CoV-2 infection and COVID-19
Johansen, M. D., Irving, A., Montagutelli, X., Tate, M. D., Rudloff, I., Nold, M. F., Hansbro, N. G., Kim, R. Y., Donovan, C., Liu, G., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00340-z · Cited by 173
Karimzadeh, S., Bhopal, R. S., & Huy, N. T. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821000790 · Cited by 192
The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant
Ali, F., Kasry, A., & Amin, M. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100086 · Cited by 163
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Xia, S., Wang, L., Zhu, Y., Lu, L., & Jiang, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01105-9 · Cited by 172
Self-citationEmerging SARS-CoV-2 variants expand species tropism to murines
Shuai, H., Chan, J. F.-W., Yuen, T. T.-T., Yoon, C., Hu, J.-C., Wen, L., Hu, B., Yang, D., Wang, Y., Hou, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103643 · Cited by 171
Self-citationMolecular insights into receptor binding of recent emerging SARS-CoV-2 variants
Han, P., Su, C., Zhang, Y., Bai, C., Zheng, A., Qiao, C., Wang, Q., Niu, S., Chen, Q., Zhang, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26401-w · Cited by 168
Self-citationMolecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V. D., Li, Y., Yuan, Z., Zhang, X., Muruato, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20789-7 · Cited by 160
Self-citationAn Overview of SARS-CoV-2 and Animal Infection
Mahdy, M. A. A., Younis, W., & Ewaida, Z. M. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.596391 · Cited by 182
The N501Y spike substitution enhances SARS-CoV-2 transmission
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · doi:10.1101/2021.03.08.434499 · Cited by 574
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 176
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 165
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 165
Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 160
Zhao, Z., Zhou, J., Tian, M., Huang, M., Liu, S., Xie, Y., Han, P., Bai, C., Han, P., Zheng, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32665-7 · Cited by 159
Self-citationPorcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines
Li, Z., Ma, Z., Li, Y., Gao, S., & Xiao, S. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104553 · Cited by 158
Self-citationGuedes, I. A., Costa, L. S. C., Santos, K. B., Karl, A. L. M., Rocha, G. K., Teixeira, I. M., Galheigo, M. M., Medeiros, V., Krempser, E., Custódio, F. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84700-0 · Cited by 161
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 158
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143
The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK
Hill, V., du Plessis, L., Peacock, T. P., Aggarwal, D., Colquhoun, R., Carabelli, A. M., Ellaby, N. A. F., Gallagher, E., Groves, N., Jackson, B., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac080 · Cited by 153
The origins of COVID‐19 pandemic: A brief overview
Hao, Y., Wang, Y., Wang, M.-Y., Zhou, L., Shi, J., Cao, J., & Wang, D. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14732 · Cited by 163
Self-citationClassification and specific primer design for accurate detection of SARS-CoV-2 using deep learning
Lopez‐Rincon, A., Tonda, A. P., Mendoza‐Maldonado, L., Mulders, D. G. J. C., Molenkamp, R., Perez-Romero, C. A., Claassen, E., Garssen, J., & Kraneveld, A. D. (2021) · Scientific Reports · doi:10.1038/s41598-020-80363-5 · Cited by 145
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Becker, M., Dulovic, A., Junker, D., Ruétalo, N., Kaiser, P. D., Pinilla, Y. T., Heinzel, C., Häring, J., Traenkle, B., Wagner, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23473-6 · Cited by 145
Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species
Liu, K., Pan, X., Li, L., Yu, F., Zheng, A., Du, P., Han, P., Meng, Y., Zhang, Y., Wu, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.031 · Cited by 143
Self-citationNanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F. L., Allison, C. C., López, E., Haycroft, E. R., O’Neill, M. T., Tan, L. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101918118 · Cited by 140
The emerging plasticity of SARS-CoV-2
McCormick, K. D., Jacobs, J. L., & Mellors, J. W. (2021) · Science · doi:10.1126/science.abg4493 · Cited by 140
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines
Zhou, W., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00644-x · Cited by 144
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Tada, T., Zhou, H., Samanovic, M. I., Dcosta, B. M., Cornelius, A. R., Herati, R. S., Mulligan, M. J., & Landau, N. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797589 · Cited by 134
SARS-CoV-2 infection and transmission in the North American deer mouse
Griffin, B. D., Chan, M., Tailor, N., Mendoza, E. J., Leung, A., Warner, B. M., Duggan, A. T., Moffat, E., He, S., Garnett, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23848-9 · Cited by 136
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 141
Mackin, S., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01359-1 · Cited by 127
The Spike of Concern—The Novel Variants of SARS-CoV-2
Winger, A., & Caspari, T. (2021) · Viruses · doi:10.3390/v13061002 · Cited by 130
Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant
Sun, Y., Lin, W., Dong, W., & Xu, J. (2021) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2021.12.001 · Cited by 123
Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates
Shou, S., Liu, M., Yang, Y., Kang, N., Song, Y., Tan, D., Liu, N., Wang, F., Liu, J., & Xie, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.626553 · Cited by 126
Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice
Huang, K., Zhang, Y., Hui, X., Zhao, Y., Gong, W., Wang, T., Zhang, S., Yang, Y., Deng, F., Zhang, Q., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103381 · Cited by 119
Guo, Y., Han, J., Zhang, Y., He, J., Yu, W., Zhang, X., Wu, J., Zhang, S., Kong, Y., Guo, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877101 · Cited by 131
Self-citationLY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsPreprint
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.442182 · Cited by 131
25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor
Zu, S., Deng, Y., Chao Hui, Z. H. O. U., Li, J., Li, L., Chen, Q., Li, X., Zhao, H. J., Gold, S., He, J., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00398-1 · Cited by 117
Self-citation
Metadata
- Authors
- Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., Li, Y., Li, X.-F., Li, J., Zhang, N.-N., Yang, X., Chen, S., Guo, Y., Zhao, G., Wang, X., Luo, D.-Y., Wang, H., Yang, X., Li, Y., Han, G., He, Y., Zhou, X., Geng, S., Sheng, X., Jiang, S., Sun, S., Qin, C.-F., & Zhou, Y.
- Affiliations
- Academy of Military Medical Sciences (CN)
- Beijing Proteome Research Center (CN)
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
- Institute of Military Cognition and Brain Sciences, Beijing 100850, China.
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing JOINN Biologics Co., Beijing 100176, China.
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Gu, Hongjing
- Chen, Qi
- Yang, Guan
- He, Lei
- Fan, Hang
- Deng, Yong-Qiang
- Jiang, Shibo
- Sun, Shihui
- Qin, Cheng-Feng
- Zhou, Yusen
- ORCID
- Gu, Hongjing
- Chen, Qi
- Yang, Guan
- He, Lei
- Fan, Hang
- Deng, Yong-Qiang
- Wang, Yanxiao
- Teng, Yue
- Zhao, Zhongpeng
- Cui, Yujun
- Li, Yuchang
- Li, Xiao-Feng
- Li, Jiangfan
- Zhang, Na-Na
- Yang, Xiaolan
- Chen, Shaolong
- Guo, Yan
- Zhao, Guangyu
- Wang, Xiliang
- Wang, Hui
- Yang, Xiao
- Li, Yan
- Han, Gencheng
- He, Yuxian
- Zhou, Xiaojun
- Jiang, Shibo
- Sun, Shihui
- Qin, Cheng-Feng
- Zhou, Yusen
- Venue
- Science
- Published
- 2020-09-25
- Volume
- 369
- Issue
- 6511
- Pages
- 1603-1607
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7574913
- OpenAlex
- W3045870925
- Cited by
- 762
- References
- 30
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 66 · 2023: 82 · 2022: 194 · 2021: 321 · 2020: 42
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82041006, 82041025)
- National Science Fund for Distinguished Young Scholars (81925025)
- National Science and Technology Major Project of China (2018ZX09711003, 2017ZX10304402)
- Beijing Municipal Science and Technology Project (201100001020004)
- National Key Plan for Scientific Research and Development of China (2016YFD0500304, 2016YFD0500306, 2020YFA0707801)
- Innovation Fund for Medical Sciences of the Chinese Academy of Medical Sciences. (2019-I2M-5-049)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, BALB/c mice, vaccine efficacy, serial passage, N501Y mutation, spike protein receptor-binding domain, interstitial lung disease, aged mice, challenge model, adaptive mutation, viral virulence
- MeSH terms
- Immunogenicity, Vaccine, Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Administration, Intranasal, Animals, Disease Models, Animal, Female, Humans, Peptidyl-Dipeptidase A, Lung, Mice, Inbred BALB C, Mice, Transgenic, Mutation, Pneumonia, Viral, Vaccines, Synthetic, Viral Vaccines, Virulence, Lung Diseases, Interstitial, Coronavirus Infections, Mice, Pandemics, High-Throughput Nucleotide Sequencing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.